How Recent Developments Are Rewriting the Story for Capricor Therapeutics [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to commercialization. Underpinning this upgrade are accelerated revenue growth assumptions, now closer to 156.4% versus 115.7% previously, along with a slightly higher discount rate near 7.03% that captures both the remaining risks and the richer opportunity set tied to HOPE-3 and potential priority review dynamics. As these moving pieces reshape the investment narrative in real time, investors may wish to stay informed to better track and interpret future shifts in Capricor's evolving story.
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline DataGlobeNewswire
- Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Capricor Therapeutics (NASDAQ:CAPR) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CAPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]Seeking Alpha
- Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 11/10/25 - In-Line
CAPR
Sec Filings
- 1/30/26 - Form S-8
- 1/26/26 - Form SCHEDULE
- 1/7/26 - Form 4
- CAPR's page on the SEC website